Employment of Latest Bioreactor Vessel for Gene and Cell Therapy Applications
By Apac CIO Outlook | Wednesday, July 24, 2019
The new bioreactor vessel is designed for optimum growth and gentle stirring of cell lines, which is a cost-effective and scalable process in developing gene therapies and cell.
Grace Johnston, Head of Marketing
FREMONT, CA: “Covering the entire value-added chain of biopharmaceuticals, Sartorius products and services ensure novel therapies reach the market faster and are more accessible to more people worldwide,” mentions Grace Johnston, Vice President Marketing at Sartorius while talking about the focus of the enterprise. Sartorius Stedium Biotech, a chief global partner of the biopharmaceutical industry recently announced the launch of a new vessel for its ambr 250 modular benchtop automated mini bioreactor system.
Ranked in APAC CIOoutlook’s Top 20 Healthcare Technology Solution Providers–2019, the company designed the single-use vessel, particularly for therapeutic cell lines. Additionally, offering the potential for accelerated process in developing gene and cell therapy applications to augment the cGMP one-time use bags and bioreactors. The business provides services and cutting-edge products for quality assurance, development, and production processes of the biopharmaceutical industry. The corporation aimed at turning science into solutions offers integrated solutions covering cell cultivation, fermentation, filtration, fluid management, and purification.
The latest vessel comprising of a sizeable pitched blade impeller has a working capacity of 100-250ML. The design enables gentle agitation and mixing without sedimentation, allowing the optimal growth of single-cell suspensions, adherent cells, or cell aggregates on microcarriers. In testing with the leading regenerative medicine organizations, the latest mini bioreactor has displayed better cell culture performance compared to the T-flask models or less analytical spinner. The performance helps improved scalability and rapid process optimization to larger bioreactors.
Ambr 250 modular system attributes a modern motor working at 100rpm-4,500rpm to maintain the culture of the cell lines, also ideal for the lower stirrer required for delicate therapeutic cell lines. The system is apt for culturing cell lines like CAR-T, HEK293, and others, comprising a range of stem cells. Furthermore, the system facilitates scalable media and supplements optimization along with process development of gene therapies and cell.
